3
Jul 2025
Shaping the future of lab automation through AI and robotics
Discover how Chemspeed is revolutionizing lab automation with AI-driven workflows, modular robotics, and more
Cancer Research
Strategic Partnerships
Mercury Pharmaceuticals business strategy is to focus on internal research and development strengths to validate product candidates through proof of concept in cancer patients. We offer access to discovery expertise and product candidates in areas of unmet medical need and distinct commercial value.
Mercury Pharmaceuticals is willing to secure partnerships to enhance our combined ability to advance novel science and accelerate the development of differentiated therapeutics. Our broad intellectual property portfolio and unique research approach enable us to be a productive partner for those seeking to advance meaningful therapeutics in cancer biology, translational oncology, and cancer prevention and control studies.
Mercury Pharmaceuticals has a strategic alliance agreement with Aesica Pharmaceuticals to advance the clinical development for the treatment of ovarian cancer and to collaborate on preclinical studies of MP13920 as a treatment for breast cancer based on positive results from a Phase 2 trial of MP13920 in ovarian cancer patients resistant to paclitaxel (Taxol), the standard of care for this disease.
If interested in learning more, please send us a message.
MERCURY trials
Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more
Cancer
Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more
Neuroscience
Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more
STAY INFORMED!
3
Jul 2025
Perceived social status influences women’s cardiovascular risk
Women who see themselves as having lower social status are more likely than other people to show early signs of heart stress linked to future disease risk, according to a new study led by researchers at McGill and Concordia universities.
3
Jul 2025
Blood viral load predicts severity of mpox symptoms
In August 2024, the World Health Organization declared a second "Public Health Emergency of International Concern" for mpox.
3
Jul 2025
European study reveals barriers to multinational clinical trials
A new study by investigators from Europe, including the Netherlands and the United Kingdom (UK), has shed light on significant ethical, administrative, regulatory, and logistical (EARL) hurdles in delivering multinational randomized clinical trials.
Why Us?
Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.